2026-07-21T07:23:04Zhttps://repisalud.isciii.es/rest/oai/requestoai:repisalud.isciii.es:20.500.12105/231132024-11-29T15:14:00Zcom_20.500.12105_2173com_20.500.12105_2051col_20.500.12105_19597
Repisalud
author
Zhou, Xiang
author
Han, Seungbin
author
Cebulla, Nadine
author
Haertle, Larissa
author
Steinhardt, Maximilian J
author
Schirmer, Daniel
author
Runau, Eva
author
Flamm, Leon
author
Terhorst, Calvin
author
Jähnel, Laura
author
Vogt, Cornelia
author
Nerreter, Silvia
author
Teufel, Eva
author
Stanojkovska, Emilia
author
Mersi, Julia
author
Munawar, Umair
author
Schindehütte, Magnus
author
Blum, Robert
author
Reinhold, Ann-Kristin
author
Scherf-Clavel, Oliver
author
Rittner, Heike L
author
Pham, Mirko
author
Rasche, Leo
author
Einsele, Hermann
author
Sommer, Claudia
author
Kortüm, K Martin
funder
German Research Foundation (DFG)
funder
Interdisciplinary Center for Clinical Research Wuerzburg (IZKF Wuerzburg)
funder
Deutsche Krebshilfe
2024-09-16T08:17:08Z
2024-09-16T08:17:08Z
2023-05-16
Biomark Res . 2023 1;11(1):52
10.1186/s40364-023-00490-9
2050-7771
Biomarker research
37194045
https://hdl.handle.net/20.500.12105/23113
We analyzed single nucleotide polymorphisms (SNPs) in PKNOX1 (rs2839629) and in the intergenic region between PKNOX1 and CBS (rs915854) by Sanger sequencing in 88 patients with multiple myeloma treated with bortezomib. All patients (n = 13) harboring a homozygous mutation in PKNOX1 (rs2839629) also had a homozygous mutated rs915854 genotype. Homozygous mutated genotypes of rs2839629 and rs915854 were significantly enriched in patients with painful peripheral neuropathy (PNP) (P < 0.0001), and homozygous mutated rs2839629 genotype was significantly enriched in patients with pain compared to patients with no pain (P = 0.04). In summary, both SNPs rs2839629 and/or rs915854 may be potential biomarkers predicting an increased risk to develop painful PNP under bortezomib.
eng
Bortezomib induced peripheral neuropathy and single nucleotide polymorphisms in PKNOX1
letter to the editor